Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. [electronic resource]
Producer: 20130322Description: 91-100 p. digitalISSN:- 1873-1686
- 1,2-Dimethylhydrazine -- administration & dosage
- Aberrant Crypt Foci -- pathology
- Adenoma -- chemically induced
- Anatomy, Cross-Sectional
- Animals
- COS Cells
- Chlorocebus aethiops
- Colon -- drug effects
- Colonic Neoplasms -- metabolism
- Cyclic AMP -- metabolism
- Diabetes Mellitus, Type 2 -- metabolism
- Dipeptidyl Peptidase 4 -- blood
- Dipeptidyl-Peptidase IV Inhibitors -- pharmacology
- Exenatide
- Female
- Glucagon-Like Peptide 1 -- analogs & derivatives
- Glucagon-Like Peptide-1 Receptor
- Glucagon-Like Peptide-2 Receptor
- Hypoglycemic Agents -- pharmacology
- Intestinal Mucosa -- drug effects
- Intestine, Small -- drug effects
- Liraglutide
- Mice
- Mice, Inbred C57BL
- Organ Size
- Peptides -- pharmacology
- Pyrazines -- pharmacology
- Receptors, Glucagon -- agonists
- Sitagliptin Phosphate
- Transfection
- Triazoles -- pharmacology
- Venoms -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.